D.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.

Daniel Dornbusch, CEO of Excision BioTherapeutics, sits down with Neil to discuss his company’s efforts to develop CRISPR-based therapies to cure HIV and other viral infectious diseases.

Khosla Ventures Partner Gwen Cheni sits down with Neil to talk her migration from Wall Street to early-stage TechBio companies, how that has shaped her investment approach in start-ups, and what emerging technologies excite her today.

Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.

On this episode, David Fajgenbaum, co-founder of Every Cure, sits down with Neil to discuss his new nonprofit, which is seeking to unlock the potential of already approved drugs to treat diseases for which they have not been approved. Fajgenbuam, co-founder and executive director of the Castleman Disease Collaborative Network and assistant professor of medicine at the University of Pennsylvania, recounts the story in his book Chasing My Cure and how he saved his own life by finding a drug to repurpose to treat his rare disease.

Joseph Antoun, CEO of L-Nutra, sits down with Neil to discuss how his company is using state-of-the art science and randomized, placebo-controlled clinical studies to use diet to extend healthy lifespans and treat a wide range of diseases.

Healthcare and medicine have long served as a hotbed of innovation. Perhaps the leading edge these days requires a paradigm shift – think digital therapeutics, Web3, the metaverse, CRISPR, Software as a Medical Device – this is the domain of Neil Littman, Founder & CEO of Bioverge, a highly curated impact-investment venture platform exclusively dedicated to healthcare and to democratizing access to investing in early stage companies and startups. The Bioverge platform serves as a decentralized network linking capital to potential investment opportunities.

Trevor Martin, Co-founder of CEO of Mammoth Biosciences, sits down with Neil to discuss the power of CRISPR as a diagnostic and therapeutic tool, his company's efforts to discover new CRISPR enzymes, and how the company is building a therapeutic pipeline through partnerships and on its own.

Bioverge is an investment and engagement platform that aims to connect the world to startup companies transforming healthcare. We’re living at an exciting time - the convergence of biology and technology is rapidly driving the healthcare industry in exciting new directions – making patient care more effective, accessible, personalized, cheaper, and faster. If you could gift the world anything, wouldn't the most impactful be the gift of better health?